In the 17 reporting periods since it became public, Palantir has beaten the analyst consensus for sales in all but one quarter.

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Burford Brothers Inc. decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 10.6% in the fourth quarter, ...

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.52 which represents a decrease of $-0.39 or -1.45% from the prior close of $26.91. The stock opened at $26.96 and touched a low of $26.42 ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The calm didn’t last long. After a brief dip, investors are bracing for further stock-market volatility in the face of a ...